

Special Issue

Vaccines Targeting Dendritic Cells

Message from the Guest Editors

Dendritic cells (DCs) act as the sentinels of the immune system and initiate and orchestrate immune responses. Current DC-based immunotherapy approaches have shown promise in cancer treatment and prevention. These approaches involve the activation of DCs following the in vitro and in vivo delivery of antigens directly to them using specialized systems such as nanoparticles or viral vectors. These strategies aim to induce humoral immunity, prime T helper cells, and/or elicit CTL responses. Broadly, the role of DCs in modulating adaptive immune responses offers new avenues for vaccine development. This Special Issue aims to compile the latest research on the ongoing advancements in vaccines targeting DCs. We welcome the submission of reviews, research articles, and short communications that highlight recent breakthroughs in DC-targeting vaccines, as well as manuscripts addressing the challenges and limitations encountered in this field.

Guest Editors

Dr. Ronald A. Backer

Luminex Corporation – A DiaSorin Company, Austin, TX 78727, USA

Prof. Dr. Björn E. Clausen

Institute for Molecular Medicine, Paul Klein Center for Immune Intervention, University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany

Deadline for manuscript submissions

31 October 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/203634

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).